Literature DB >> 30108871

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Robin A Fairhurst1, Thomas Knoepfel1, Catherine Leblanc1, Nicole Buschmann1, Christoph Gaul1, Jutta Blank1, Inga Galuba1, Jörg Trappe1, Chao Zou1, Johannes Voshol1, Christine Genick1, Peggy Brunet-Lefeuvre1, Francis Bitsch1, Diana Graus-Porta1, Pascal Furet1.   

Abstract

A diverse range of selective FGFR4 inhibitor hit series were identified using unbiased screening approaches and by the modification of known kinase inhibitor scaffolds. In each case the origin of the selectivity was consistent with an interaction with a poorly conserved cysteine residue within the middle-hinge region of the kinase domain of FGFR4, at position 552. Targeting this region identified a non-covalent diaminopyrimidine series differentiating by size, an irreversible-covalent inhibitor in which Cys552 undergoes an SNAr reaction with a 2-chloropyridine, and a reversible-covalent inhibitor series in which Cys552 forms a hemithioacetal adduct with a 2-formyl naphthalene. In addition, the introduction of an acrylamide into a known FGFR scaffold identified a pan-FGFR inhibitor which reacted with both Cys552 and a second poorly conserved cysteine on the P-loop of FGFR4 at position 477 which is present in all four FGFR family members.

Entities:  

Year:  2017        PMID: 30108871      PMCID: PMC6072211          DOI: 10.1039/c7md00213k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  24 in total

Review 1.  Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.

Authors:  Renato A Bauer
Journal:  Drug Discov Today       Date:  2015-05-19       Impact factor: 7.851

Review 2.  Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

Authors:  Edward P Carter; Abbie E Fearon; Richard P Grose
Journal:  Trends Cell Biol       Date:  2014-11-29       Impact factor: 20.808

3.  Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.

Authors:  Julie A Tucker; Tobias Klein; Jason Breed; Alexander L Breeze; Ross Overman; Chris Phillips; Richard A Norman
Journal:  Structure       Date:  2014-11-20       Impact factor: 5.006

4.  Structural analysis of the human fibroblast growth factor receptor 4 kinase.

Authors:  E Lesca; A Lammens; R Huber; M Augustin
Journal:  J Mol Biol       Date:  2014-09-16       Impact factor: 5.469

Review 5.  Targeting the fibroblast growth factor receptors for the treatment of cancer.

Authors:  Steven M Lemieux; M Kyle Hadden
Journal:  Anticancer Agents Med Chem       Date:  2013-06       Impact factor: 2.505

6.  2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Authors:  Cheng Mo; Zhang Zhang; Christopher P Guise; Xueqiang Li; Jinfeng Luo; Zhengchao Tu; Yong Xu; Adam V Patterson; Jeff B Smaill; Xiaomei Ren; Xiaoyun Lu; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2017-03-31       Impact factor: 4.345

7.  First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Authors:  Margit Hagel; Chandra Miduturu; Michael Sheets; Nooreen Rubin; Weifan Weng; Nicolas Stransky; Neil Bifulco; Joseph L Kim; Brian Hodous; Natasja Brooijmans; Adam Shutes; Christopher Winter; Christoph Lengauer; Nancy E Kohl; Timothy Guzi
Journal:  Cancer Discov       Date:  2015-03-16       Impact factor: 39.397

8.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.

Authors:  Katrina Nicholes; Susan Guillet; Elizabeth Tomlinson; Kenneth Hillan; Barbara Wright; Gretchen D Frantz; Thinh A Pham; Lisa Dillard-Telm; Siao Ping Tsai; Jean-Philippe Stephan; Jeremy Stinson; Timothy Stewart; Dorothy M French
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Authors:  J Michael Bradshaw; Jesse M McFarland; Ville O Paavilainen; Angelina Bisconte; Danny Tam; Vernon T Phan; Sergei Romanov; David Finkle; Jin Shu; Vaishali Patel; Tony Ton; Xiaoyan Li; David G Loughhead; Philip A Nunn; Dane E Karr; Mary E Gerritsen; Jens Oliver Funk; Timothy D Owens; Erik Verner; Ken A Brameld; Ronald J Hill; David M Goldstein; Jack Taunton
Journal:  Nat Chem Biol       Date:  2015-05-25       Impact factor: 15.040

10.  Quantifying tetrahedral adduct formation and stabilization in the cysteine and the serine proteases.

Authors:  Jennifer A Cleary; William Doherty; Paul Evans; J Paul G Malthouse
Journal:  Biochim Biophys Acta       Date:  2015-07-11
View more
  6 in total

1.  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Authors:  Xiaojing Lin; Yuliana Yosaatmadja; Maria Kalyukina; Martin J Middleditch; Zhen Zhang; Xiaoyun Lu; Ke Ding; Adam V Patterson; Jeff B Smaill; Christopher J Squire
Journal:  ACS Med Chem Lett       Date:  2019-07-03       Impact factor: 4.345

2.  2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

Authors:  Thomas Knoepfel; Pascal Furet; Robert Mah; Nicole Buschmann; Catherine Leblanc; Sebastien Ripoche; Diana Graus-Porta; Markus Wartmann; Inga Galuba; Robin A Fairhurst
Journal:  ACS Med Chem Lett       Date:  2018-02-01       Impact factor: 4.345

3.  Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Authors:  Wuqing Deng; Xiaojuan Chen; Kaili Jiang; Xiaojuan Song; Minhao Huang; Zheng-Chao Tu; Zhang Zhang; Xiaojing Lin; Raquel Ortega; Adam V Patterson; Jeff B Smaill; Ke Ding; Suming Chen; Yongheng Chen; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2021-03-22       Impact factor: 4.345

Review 4.  Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.

Authors:  Shuyan Dai; Zhan Zhou; Zhuchu Chen; Guangyu Xu; Yongheng Chen
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

Review 5.  Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.

Authors:  Jia Zheng; Wei Zhang; Linfeng Li; Yi He; Yue Wei; Yongjun Dang; Shenyou Nie; Zufeng Guo
Journal:  Front Chem       Date:  2022-04-14       Impact factor: 5.545

6.  Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1.

Authors:  Adrian Hall; Jan Abendroth; Madison J Bolejack; Tom Ceska; Sylvie Dell'Aiera; Victoria Ellis; David Fox; Cyril François; Muigai M Muruthi; Camille Prével; Karine Poullennec; Sergei Romanov; Anne Valade; Alain Vanbellinghen; Jason Yano; Martine Geraerts
Journal:  ACS Med Chem Lett       Date:  2022-06-25       Impact factor: 4.632

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.